Altus Announces the Issuance of Additional United States and European Patents Covering its Proprietary Protein Crystallization Technology.Business Editors/Health/Medical Writers BIOWIRE2K CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 3, 2003 Altus(R) Biologics Inc. announces the addition of United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. and European patents to its protein crystallization Crystallization The formation of a solid from a solution, melt, vapor, or a different solid phase. Crystallization from solution is an important industrial operation because of the large number of materials marketed as crystalline particles. technology portfolio. United States patent 6,359,118 was issued for the invention, "Carbohydrate cross-linked glycoprotein glycoprotein (glī'kōprō`tēn), organic compound composed of both a protein and a carbohydrate joined together in covalent chemical linkage. crystals," and patent 6,500,933 was issued for the invention, "Methods of preparing carbohydrate cross-linked glycoprotein crystals." United States patent 6,541,606 was issued for the invention, "Stabilized protein crystals, formulations containing them, and methods of making them." In addition, the European Patent Office issued patent EP 0550 450 B1 for the invention, "Use of cross-linked crystals as a novel form of enzyme immobilization Immobilization Definition Immobilization refers to the process of holding a joint or bone in place with a splint, cast, or brace. This is done to prevent an injured area from moving while it heals. ." These patents strengthen Altus' intellectual property portfolio covering the Company's proprietary protein crystallization technology, including its application to the oral and parenteral parenteral /pa·ren·ter·al/ (pah-ren´ter-al) not through the alimentary canal, but rather by injection through some other route, as subcutaneous, intramuscular, etc. par·en·ter·al adj. 1. delivery of protein therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. . Dr. Alexey Margolin, Altus' Vice President of Science commented, "These patents cover important technology that can be applied to the oral delivery of proteins to treat diseases, particularly gastrointestinal and metabolic diseases metabolic disease, n a disorder that causes dysfunction of the metabolic action of the body, resulting in loss of control of homeostasis. paraneoplastic syndrome , that would otherwise be untreatable Un`treat´a`ble a. 1. Incapable of being treated; not practicable. with protein therapeutics. This technology has also been shown to be of significant benefit for parenteral protein drug delivery by enabling improved routes of administration as well as controlling the release of these proteins." Dr. Margolin added, "We continue to aggressively build our intellectual property portfolio to support the global development of products developed by Altus as well as our partners." About Altus Altus Biologics Inc. is a pharmaceutical company that uses its powerful and proprietary protein crystallization technology to develop innovative, orally delivered protein therapies. Altus' protein crystallization technology, known as Crystalomics(TM), enables the rapid commercialization of high-value orally delivered protein-based products by creating highly stable protein therapeutics. The technology enables oral delivery of the protein to the gastrointestinal tract gastrointestinal tract n. The part of the digestive system consisting of the stomach, small intestine, and large intestine. Gastrointestinal tract to provide a localized or topical effect within the gastrointestinal (GI) lumen. Through its branded products portfolio, the Company's vision is to be the worldwide leader in the rapid and efficient development of valuable orally delivered proteins for the treatment of gastrointestinal and metabolic diseases. The Company has a series of products in various stages of research and development, all leveraging the Crystalomics technology. Altus' protein crystallization technology is also proving to be a valuable tool for parenteral delivery of proteins by allowing them to be delivered in a more patient friendly manner and also allowing controlled release formulations to reduce the number of injections. Altus has numerous development partners and is constantly evaluating the opportunity to expand its product development efforts through partnering opportunities. For more information on Altus, visit www.altus.com. Altus(R) and Crystalomics(TM) are trademarks of Altus Biologics Inc. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion